Please take a moment to review the latest ASCO News
- Expanded Open Enrollment, Special Enrollment Periods for Certain Health Insurance Exchanges Increase Access to Cancer Care
- FDA Approves Pembrolizumab for High-risk Early-stage Triple-negative Breast Cancer
- ASCO Joins Statement Supporting Mandatory Health Employer COVID-19 Vaccination
- Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma Granted FDA Regular Approval
- Lawmakers Urged to Reconsider Using Medicare Sequestration to Pay for Infrastructure Package
- Oral Parity Bill Reintroduced in House
- 2022 Hospital Outpatient Payment Proposal Focuses on Implementing the Radiation Oncology Model, 340B, Price Transparency
- Proposed ARPA-H Should Focus on High-Risk, High-Reward Research That Fills Gap in Current Research Enterprise, ASCO Says in Comments to Congress
- FDA Approves Belumosudil for Chronic Graft-versus-host Disease
- Oncology Practices Nationwide Show High Interest in Diversifying Cancer Clinical Trials
- Support Increased Funding for Cancer Research in Fiscal Year 2022
- Negative 2% Overall Impact Estimated for Hematology/Oncology, Negative 5% for Radiation Oncology, in 2022 Medicare Physician Payment Proposal
- New ASCO-COA Oncology Medical Home Standards Set High Bar, Offers Roadmap for Comprehensive High-quality, Patient-Centered Cancer Care Delivery
- State Advocacy Update: Cancer Policy Advancements from Arizona, Pennsylvania, and Oregon
- Surprise Billing Rule Covers Emergency Services, Cost Sharing, Out-of-Network Rate Determination